Activities of BioValley Deutschland e.V.

BioValley Deutschland e.V. offers its members and guests different event formats:

  1. The core activity of the BioValley events are the so-called BioValley Regulars Table seminars. In most cases, they take place in Freiburg and in the BioValley Meeting places in Lörrach.
    The concept of these events, which take place 8-10 times per year, is simple but successful. After short presentations of approx. 35 minutes from one or two companies, start-ups or scientific institutions, a discussion follows and finally a get-together with Baden wine rounds up the meetings.
  1. A further event highlight is the BioValley Companies Day, which takes place once a year, alternating with our partners in France and Switzerland in hosting the event.
    These BioValley Companies Days are one-day events based on the Elevator pitches principle. Approximately 30-36 Life Science Companies or scientific institutions present for maximally 8 minute presentations to a chosen public. Coffee breaks and a midday meal allow possibilities for communication and exchange of information.
  1. As partners of the Swiss (BioValley Basel) and Alsace biovalleys (BioValley France) our members can also participate in their events. BioValley France and BIO-PRO Baden-Württemberg organize the successful Meet and Match events in Strasburg, offering biotechnology and medical technology presentations combined with discussions and networking forums. https://www.biovalley-france.com/fr/agenda
    BioValley Basel meetings include Matching BioTech Angels and Companies events, see: https://biovalley.ch/events-news
6/25

Free event

BioValley Stammtisch Freiburg: BioCopy GmbH: Safety First: Developing Next-Generation TCRm Antibodies for Cancer with Highest Precision and Selectivity

Tuesday, 27. May 2025 - 18:00
until 19:30
Book now

Titel: BioCopy GmbH: Safety First: Developing Next-Generation TCRm Antibodies for Cancer with Highest Precision and Selectivity

Referent: Dr. Günter Roth, Managing Director BioCopy GmbH

Zum Thema: 

Peptide–HLA (pHLA) complexes—formed by short intracellularly derived peptides presented on the cell surface by HLA molecules—are central to T-cell based immune surveillance and represent a largely untapped class of highly specific targets for immunotherapy. Unlike conventional surface antigens, pHLAs provide access to intracellular, often tumor-specific epitopes (e.g. tumor neoantigenes or cancer testis antigens), opening novel avenues for the treatment of cancer and infectious diseases.

pHLA-targeting modalities such as TCR-engineered T cells (e.g., Afami-cel), bispecific T-cell engagers (e.g., Kimmtrak), and T-cell receptor–mimic (TCRm) antibodies hold significant therapeutic promise. However, their development is challenged as any off-target reactivity can induce massive cytotoxic effects by attacking healthy tissues – leading to severe side effects and posing serious risks to patient safety and survival. These side-effects are basically limiting the unprecedented power of T-cell drugs to fight cancer – as in theory – these drugs simply lead the T-cells to destroy the cancer. In an ideal world, the patients immune system would, after application of the according drug, heal himself from cancer.

BioCopy accepts this challenge with a comprehensive discovery platform—ValidaTe—which integrates AI-based off-target prediction, ultra–high-throughput chip-based pHLA screening, and advanced antibody engineering to generate TCRm antibodies with a minimum of off-target reactivity - and thus a maximum safety and specificity. When formatted as T-cell engagers, BioCopy’s TCRms demonstrate exceptional target selectivity and strong therapeutic potential.

Located near Freiburg, BioCopy is a mid-sized biotech company recognized for its proprietary pHLA-screening technologies. The company is guided by a distinguished Board of Directors, including former Novartis CEO Rainer Boehm, and a strong Scientific Advisory Board including Nobel Laureate Prof. Hartmut Michel.

Sign up now!

Free Event

Additional dates

BioValley offers a variety of activities to bring together science and technology from universities, research institutes, large and small life science companies, as well as public facilities.